Taysha Gene Therapies, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Taysha Gene Therapies, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $0.00.
- Taysha Gene Therapies, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $176.00K, a 134.67% increase year-over-year.
- Taysha Gene Therapies, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $0.00.
- Taysha Gene Therapies, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $84.00K, a 33.33% increase year-over-year.
- Taysha Gene Therapies, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $159.00K, a 78.65% increase from fiscal 2024.
- Taysha Gene Therapies, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $89.00K, a 30.88% increase from fiscal 2023.
- Taysha Gene Therapies, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $68.00K, a 73.12% decline from fiscal 2022.
- Taysha Gene Therapies, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $253.00K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $260.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $176.00K 10-Q · filed 2026-05-06 | $260.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $159.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $84.00K 10-Q · filed 2025-11-04 | $159.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $138.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $75.00K 10-Q · filed 2026-05-06 | $138.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $89.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $63.00K 10-Q · filed 2025-11-04 | $89.00K derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $44.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $26.00K 10-Q · filed 2025-05-15 | $44.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $68.00K 10-K · filed 2025-02-26 |
| 2023-09-30 | $18.00K 10-Q · filed 2024-11-13 | $68.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $303.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $50.00K 10-Q · filed 2024-05-14 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $253.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | $253.00K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |